EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales

Ioannis Baltas iD, Deny Tsakri, Sofia Vourli, Himani Solanki, Evelyn Murrell, Eftychia Kiousi, Zacharias Tsakris, Gabriella Kuczmar, Nikoletta Smyrni, Ioannis Skiadas, Vassilios Grammelis, James Hatcher iD und 4 weitere

Journal of Antimicrobial Chemotherapy · 02.12.2025 · 80 (12) · 3273-3277

DOI: 10.1093/jac/dkaf361 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 26.09.2025. Verfasst von Ioannis Baltas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity & Inflammation Department, UCL Institute of Child Health, London, UK. Hauptthemen laut MEDLINE: Aztreonam, Azabicyclo Compounds, Anti-Bacterial Agents, Enterobacteriaceae. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, Wellcome Trust, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Aztreonam/avibactam is a novel β-lactam/β-lactamase inhibitor (BL/BLI) combination active against carbapenem-resistant Enterobacterales (CRE), including MBL-producing isolates. In May 2024, EUCAST published Enterobacterales breakpoints for aztreonam/avibactam. This study aimed to assess the performance of commercially available disc diffusion (DD) against broth microdilution (BMD) using the latest EUCAST breakpoints.

Methods

We tested 278 CRE causing infections in 17 Greek ICUs between 2021 and 2023, using 30/20 μg aztreonam/avibactam discs and BMD according to EUCAST methodology and EUCAST version 15.0 breakpoints.

Results

Most isolates were identified as Klebsiella pneumoniae (97.8%), and 98.9% produced carbapenemases, including 46.4% KPC, 20.1% NDM, 5.4% VIM and 27% multiple carbapenemases. Using BMD, 94.2% of isolates were susceptible to aztreonam/avibactam. Conversely, using DD, 66.9% were susceptible, 33.1% resistant and 27% within the area of technical uncertainty (ATU). Most isolates in the ATU were KPC-producing (68%) or KPC and MBL-producing (29.3%). All isolates in the ATU (22–24 mm) tested susceptible by BMD (MIC ≤ 4 mg/L). One isolate exhibited resistance by DD (20 mm), but was susceptible by BMD. Categorical agreement (CA) was 72.7%, with 29% major errors (MEs) and 0% very major errors (VMEs). Using a breakpoint of 22 mm, CA, ME and VME were 99.6%, 0.4% and 0%, respectively.

Conclusions

Aztreonam/avibactam showed potent in vitro activity against MBL- and KPC-producing Enterobacterales. Using the 2025 EUCAST breakpoint, all isolates in the ATU tested susceptible by BMD, leading to high MEs of the DD method. A 22 mm breakpoint would have corrected this discrepancy in our cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AztreonamAzabicyclo CompoundsAnti-Bacterial AgentsEnterobacteriaceaeDisk Diffusion Antimicrobial Testsbeta-Lactamase InhibitorsHumansMicrobial Sensitivity TestsEnterobacteriaceae Infectionsbeta-LactamasesCarbapenem-Resistant EnterobacteriaceaeDrug CombinationsGreece

Substanzen

AztreonamAzabicyclo CompoundsAnti-Bacterial Agentsavibactambeta-Lactamase Inhibitorsbeta-LactamasesDrug Combinations

Autor:innen und Institutionen

  • Infection, Immunity & Inflammation Department, UCL Institute of Child Health, London, UK.
  • Institute of Biosciences and Applications, NCSR 'Demokritos', Athens, Greece.
  • Department of Clinical Microbiology, Great Ormond Street Hospital for Children, London, UK.
  • Pfizer Hellas, Athens, Greece.
  • Department of Microbiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Ioannis Baltas, James Hatcher

Förderung

  • National Institute of Allergy and Infectious Diseases
  • Wellcome Trust
  • NIH HHS
  • GOSH/ICH Biomedical Research Centre
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Baltas, I., Tsakri, D., Vourli, S., Solanki, H., Murrell, E., Kiousi, E., Tsakris, Z., Kuczmar, G., Smyrni, N., Skiadas, I., Grammelis, V., Hatcher, J., Menegas, D., Tsakris, A., Vrioni, G., & Grandjean, L. (2025). Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales. Journal of Antimicrobial Chemotherapy, 80(12), 3273-3277. https://doi.org/10.1093/jac/dkaf361

Vancouver

Baltas I, Tsakri D, Vourli S, Solanki H, Murrell E, Kiousi E, et al. Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales. Journal of Antimicrobial Chemotherapy. 2025;80(12):3273-3277. doi:10.1093/jac/dkaf361

BibTeX
@article{Baltas2025,
  author = {Baltas, Ioannis and Tsakri, Deny and Vourli, Sofia and Solanki, Himani and Murrell, Evelyn and Kiousi, Eftychia and Tsakris, Zacharias and Kuczmar, Gabriella and Smyrni, Nikoletta and Skiadas, Ioannis and Grammelis, Vassilios and Hatcher, James and Menegas, Damianos and Tsakris, Athanasios and Vrioni, Georgia and Grandjean, Louis},
  title = {Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {12},
  pages = {3273--3277},
  doi = {10.1093/jac/dkaf361}
}
Kostenlos starten →